Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
Reads0
Chats0
TLDR
Improved understanding of prognostic and predictive factors may enable delivery of a more personalized treatment for the individual patient and a more cost-effective use of health care resources.Abstract:
The skeleton is the most common organ to be affected by metastatic cancer and the site of disease that produces the greatest morbidity. Skeletal morbidity includes pain that requires radiotherapy, hypercalcemia, pathologic fracture, and spinal cord or nerve root compression. From randomized trials in advanced cancer, it can be seen that one of these major skeletal events occurs on average every 3 to 6 months. Additionally, metastatic disease may remain confined to the skeleton with the decline in quality of life and eventual death almost entirely due to skeletal complications and their treatment. The prognosis of metastatic bone disease is dependent on the primary site, with breast and prostate cancers associated with a survival measured in years compared with lung cancer, where the average survival is only a matter of months. Additionally, the presence of extraosseous disease and the extent and tempo of the bone disease are powerful predictors of outcome. The latter is best estimated by measurement of bone-specific markers, and recent studies have shown a strong correlation between the rate of bone resorption and clinical outcome, both in terms of skeletal morbidity and progression of the underlying disease or death. Our improved understanding of prognostic and predictive factors may enable delivery of a more personalized treatment for the individual patient and a more cost-effective use of health care resources.read more
Citations
More filters
Journal Article
Malignant bone pain: pathophysiology and treatment.
TL;DR: The use of analgesics according to the WHO ladder is recommended and non‐steroidal anti‐inflammatory drugs (NSAIDs) have a specific efficacy in malignant bone pain.
Journal ArticleDOI
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Allan Lipton,Karim Fizazi,Alison Stopeck,David H. Henry,Janet E. Brown,Denise A. Yardley,Gary Richardson,Salvatore Siena,Pablo Maroto,Michael Clemens,Boris Bilynskyy,Veena Charu,Philippe Beuzeboc,Michael Rader,María Viniegra,Fred Saad,Chunlei Ke,Ada Braun,Susie Jun +18 more
TL;DR: Denosumab was superior to zoledronic acid in preventing SRE with favourable safety and convenience in patients with bone metastases from advanced cancer.
Journal ArticleDOI
Bone health in cancer patients: ESMO Clinical Practice Guidelines
TL;DR: Through optimum multidisciplinary management of patients with bone metastases, including the use of bone-targeted treatments such as potent bisphosphonates or denosumab, it has been possible to transform the course of advanced cancer for many patients resulting in a major reduction in skeletal complications, reduced bone pain and improved quality of life.
Journal ArticleDOI
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
Matti Aapro,Per-Anders Abrahamsson,Jean-Jacques Body,Robert E. Coleman,Ramon Colomer,Luís Costa,L. Crino,Luc Dirix,Michael Gnant,Julie R. Gralow,Peyman Hadji,Gabriel N. Hortobagyi,Walter Jonat,Allan Lipton,Alain Monnier,Alexander H.G. Paterson,René Rizzoli,Fred Saad,Beat Thürlimann +18 more
TL;DR: An interdisciplinary expert panel of clinical oncologists and of specialists in metabolic bone diseases assessed the widespread evidence and information on the efficacy of BP in the metastatic and nonmetastatic setting, as well as ongoing research on the adjuvant use of BP and recommends amino-bisphosphonates for patients with metastatic bone disease from breast cancer and zoledronic acid for Patients with other solid tumours as primary disease.
Journal ArticleDOI
NCCN Task Force Report: Bone Health in Cancer Care
Julie Gralow,J. Sybil Biermann,Azeez Farooki,Monica Fornier,Robert F. Gagel,Rashmi Kumar,Georgia Litsas,Rana R. McKay,Donald A. Podoloff,Sandy Srinivas,Catherine Van Poznak +10 more
TL;DR: This report summarizes issues surrounding bone health in cancer care presented and discussed during this NCCN Bone Health in Cancer Care Task Force meeting in December 2012.
References
More filters
Journal ArticleDOI
Cancer statistics, 1999.
TL;DR: The Surveillance Research Program of the American Cancer Society's Department of Epidemiology and Surveillance Research reports its 33rd annual compilation of cancer frequency, incidence, mortality, and survival data for the United States.
Journal ArticleDOI
A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
Fred Saad,Donald M. Gleason,Robin Murray,Simon Tchekmedyian,Peter Venner,Louis Lacombe,Joseph L. Chin,Jeferson J. Vinholes,J. Allen Goas,Bee Chen +9 more
TL;DR: Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases and urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic Acid at either dose.
Journal ArticleDOI
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
E. D. Crawford,Mario A. Eisenberger,David G. McLeod,J T Spaulding,Ralph C. Benson,F A Dorr,Brent A. Blumenstein,M A Davis,P J Goodman +8 more
TL;DR: Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade.
Journal ArticleDOI
The clinical course of bone metastases from breast cancer.
TL;DR: The duration of survival in patients with carcinoma of the breast seen in this Unit was similar to responding patients, suggesting a tumour response may occur in the absence of discernable radiological evidence of healing.
Journal ArticleDOI
American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer
Bruce E. Hillner,James N. Ingle,Rowan T. Chlebowski,Julie Gralow,Gary C. Yee,Nora A. Janjan,Jane A. Cauley,Brent A. Blumenstein,Kathy S. Albain,Allan Lipton,Susan Brown +10 more
TL;DR: Bisphosphonates provide a supportive, albeit expensive and non-life-prolonging, benefit to many patients with bone metastases and an algorithm for patient management to maintain bone health is recommended.